For the Inventor, By the Inventor

Enter assignee name

Toorak, Victoria, Australia

Antisense Therapeutics Limited

USPTO Granted Patents = 17

CIPO Patents = 3

EPO Patents = 9

Forward Citations = 16

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

George Tachas (14 out of 15 patents)

Kenneth W Dobie (7 out of 76 patents)

Ravi Jain (4 out of 22 patents)

4. Christopher Belyea (3 out of 3 patents)

5. Mark Heffernan (3 out of 3 patents)

6. Ety Klinger (2 out of 11 patents)

7. Shoshi Tessler (2 out of 2 patents)

8. Mark Paul Diamond (2 out of 2 patents)

9. Jeffrey R Crosby (1 out of 9 patents)

10. Yong-Mi Kim (1 out of 1 patent)

11. Christopher John Wraight (1 out of 5 patents)

12. Nicholas M Dean (1 out of 54 patents)

13. Lynne Maree Atley (1 out of 1 patent)

14. Hussein Hallak (1 out of 4 patents)

15. James G Karras (1 out of 20 patents)

17 patents: Sort by Forward Citations

1. 11976281 - Therapeutic uses and methods (2024-05-07),

2. 11891606 - Methods for treating multiple sclerosis using antisense oligonucleotides (2024-02-06),

3. 11041156 - Mobilizing leukemia cells (2021-06-22),

4. 9988635 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2018-06-05),

5. 9821034 - Combination therapy (2017-11-21),

6. 9717778 - Combination therapy (2017-08-01),

7. 9371530 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2016-06-21),

8. 9084770 - Modulation of insulin like growth factor I receptor expression in cancer (2015-07-21),

9. 8765700 - Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions (2014-07-01),

10. 8759314 - Methods for treating multiple sclerosis using antisense oligonucleotides (2014-06-24),

11. 8637484 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2014-01-28),

12. 8623836 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2014-01-07),

13. 8415314 - Methods for treating multiple sclerosis using antisense oligonucleotides (2013-04-09),

14. 8299039 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2012-10-30),

15. 8217017 - Modulation of insulin like growth factor I receptor expression (2012-07-10),

Antisense Therapeutics Limited is a biopharmaceutical company focused on developing and commercializing novel antisense therapeutics to treat a range of diseases. Their innovative approach involves the use of antisense technology to interfere with the production of disease-causing proteins at the DNA level. Through their extensive research and development activities, Antisense Therapeutics aims to bring effective treatments to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

17 Patents

#2 in Toorak, Victoria

#205 in Australia

#34,861 in the World

Toorak, Victoria, Australia

Antisense Therapeutics Limited

Forward Citations = 16

20 inventors:

George Tachas (14 out of 15 patents)

Kenneth W Dobie (7 out of 76 patents)

Ravi Jain (4 out of 22 patents)

4. Christopher Belyea (3 out of 3 patents)

5. Mark Heffernan (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…